Search Results 1291-1300 of 17131 for Birth Control Evolution
... controlled trial with 2:1 (regorafenib : placebo) ... Poorly-controlled ... Women must be post-menopausal infertile, or use a reliable means of contraception.
Persons of childbearing potential who are unwilling to employ adequate contraception for at least 3 months after the last dose of the study drug. Co-morbid ...
The purpose of this study is to determine the effect of endogenous glucagon-like peptide-1 on active intestinal glucose transport and on intestinal permeability ...
This includes studies on the development of children with spina bifida who had surgery before they were born compared with those who had surgery after birth.
Patients with no motor control of fingers. Patient with known/confirmed active conductive hearing loss. Negative MITOP test result (only for the ...
* Contraceptive use by male or female participants should be consistent with local regulations regarding the methods of contraception for those ...
Women of childbearing potential must have negative serum pregnancy test prior to dosing at W1D1 and be willing to use an adequate method of contraception ...
About this study. This study is being done to collect and store samples of genitourinary (GU) tissues (and potentially blood) for current and future ...
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...
Men or women of childbearing potential who are unwilling to employ adequate contraception. Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.